Meta description: Warsaw-based Jutro Medical has extended its Series A to €36 million, aiming to acquire and integrate AI-powered primary care clinics across Europe.
Jutro Medical, an AI-focused primary care platform headquartered in Warsaw, has closed a €24 million extension to its Series A funding round. This brings total Series A proceeds to €36 million and sets the stage for aggressive clinic acquisitions across Poland and later Europe. Investors, founders, and industry analysts will note the strategic mix of equity and debt positioned to fuel growth and operational integration.
Who invested in this round?
The €24 million Series A extension was led by Warsaw Equity Group. Participation came from Vinci, naturalX Health Ventures, Fluent Ventures, Aternus, KAYA VC, and Inovo VC. Debt financing support was provided by mBank and Orbit Capital. The combined rounds position the company with €36 million in capital under Series A.
This investor mix shows strong regional and sector expertise. Equity partners bring strategic healthtech connections, while debt funding structures provide additional flexibility for acquisition-driven expansion.
What does this financing mean for operations?
Jutro Medical is building a unified network of AI-supported clinics. The funds will allow for continued acquisition of existing practices, integrating them into a single platform that blends electronic health records and automation tools. This model targets improved consultation management, prescription processing, diagnostics ordering, and administrative handling.
Operationally, owning both technology and clinics enables tighter quality control and margin improvement. By integrating AI into routine tasks, the company frees physician time for direct patient care. Metrics from recent months show the platform supported thousands of monthly interactions and 1,500 physician visits, with high satisfaction scores.
How will growth targets be reached?
The near-term plan involves acquiring more than 20 clinics within Poland over the next year. Post domestic consolidation, the business intends to expand across European markets, aiming for €1 billion in revenue long term while keeping EBITDA close to break-even. Reported year-over-year growth stands at 270 percent, underlining the scale of its operational momentum.
The acquisition strategy is backed by technology foundations that have been in development for four years, making integration faster and reducing disruption during onboarding of new clinics.
FAQ
1. How much total funding has Jutro Medical raised in Series A?
Series A totals €36 million after the recent €24 million extension.
2. What type of financing structures are involved?
The round includes both equity and debt financing.
3. Which investors are part of the Series A extension?
Participants include Warsaw Equity Group, Vinci, naturalX Health Ventures, Fluent Ventures, Aternus, KAYA VC, Inovo VC, mBank, and Orbit Capital.
4. What is the company’s expansion goal?
To acquire clinics in Poland and later across Europe, aiming for €1 billion revenue while maintaining operational efficiency.
Key takeaways
Jutro Medical’s €36 million Series A funding marks a significant step in scaling AI-integrated primary care across Europe. The blend of equity and debt strengthens both capability and resilience. Clinic acquisitions, supported by mature tech infrastructure, align with its goal to improve margins and patient care access while sustaining rapid growth.
Disclaimer
This content is for informational purposes only and should not be considered financial advice.